ReviewTherapeutic advances in chronic disease2014
Glaucoma management: relative value and place in therapy of available drug treatments.
Review in Therapeutic advances in chronic disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02679482 (Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma
Who cites it
38 citing papers in PubMed, 90 citations in OpenAlex.
- Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET).Advances in therapy · 2023Trial
- Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.Advances in therapy · 2021Trial
- [Microinvasive glaucoma surgery-Efficacy of trabecular stents in combined interventions : A clinical study on 65 eyes].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019Trial
- Dissecting corneal drug permeability under experimental variability and drug cold-start challenges via hybrid machine learning.Drug delivery and translational research · 2026Article
- Management and outcomes of primary open-angle glaucoma.Journal of family medicine and primary care · 2026Review
- A Comprehensive Review of the Clinical Evidence Comparing Benzalkonium Chloride-Preserved and Benzalkonium Chloride-Free Latanoprost in the Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Progress in Glaucoma Management in the Era of Value-Based Healthcare.Journal of clinical medicine · 2025Article
- Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Neuroprotective and intraocular pressure lowering effects of dual-functional memantine nitrate MN-08 on the experimental models of glaucoma.Scientific reports · 2025Article
- Glaucoma: Current and New Therapeutic Approaches.Biomedicines · 2024Review
- Exploring the Ocular Surface Microbiome and Tear Proteome in Glaucoma.International journal of molecular sciences · 2024Article
- Intraocular Pressure-Lowering and Retina-Protective Effects of Exosome-Rich Conditioned Media from Human Amniotic Membrane Stem Cells in a Rat Model of Glaucoma.International journal of molecular sciences · 2023Article
- Extracellular vesicles as a new horizon in the diagnosis and treatment of inflammatory eye diseases: A narrative review of the literature.Frontiers in immunology · 2023Review
- Short-term report of early glaucoma surgery with a clear lens extraction and an intraocular lens, OMNI canaloplasty, and a HYDRUS microstent: a case series in younger patients.Frontiers in ophthalmology · 2023Article
- Unmet needs in glaucoma therapy: The potential role of hydrogen sulfide and its delivery strategies.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- The role of EPThe British journal of ophthalmology · 2021Article
- Transcorneal Electrical Stimulation Reduces Neurodegenerative Process in a Mouse Model of Glaucoma.Annals of biomedical engineering · 2021Article
- Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development.Frontiers in medicine · 2021Review
- Drug Repurposing on G Protein-Coupled Receptors Using a Computational Profiling Approach.Frontiers in molecular biosciences · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lowering intraocular pressure (IOP) is the only proven therapeutic intervention for glaucomatous optic neuropathy. Despite advances in laser and microsurgical techniques, medical IOP reduction remains the first-line treatment option for the majority of patients with open-angle glaucoma. Prostaglandin analogs are the most efficacious topical agents and carry a remarkable safety profile. Topical beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors are often employed as adjunctive agents for further IOP control. Newer preserved and nonpreserved formulations are available and appear to be less toxic to the ocular surface. Oral carbonic anhydrase inhibitors, miotic agents, and hyperosmotics are infrequently used due to a host of potentially serious adverse events. Medical therapies on the horizon include rho-kinase inhibitors, neuroprotective interventions, and gene therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.